Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer

  • STATUS
    Recruiting
  • End date
    May 30, 2022
  • participants needed
    154
  • sponsor
    Chinese University of Hong Kong
Updated on 4 February 2021
Investigator
Grace LH Wong, MD
Primary Contact
Endoscopy Center, Prince of Wales Hospital, Shatin (8.7 mi away) Contact

Summary

Patients with a history of idiopathic gastroduodenal ulcer bleeding face an increased risk of recurrent ulcer gastrointestinal bleeding. Our ongoing clinical trial demonstrates a possible reduced risk of recurrent idiopathic gastroduodenal ulcer bleeding with proton pump inhibitor (PPI), yet there is a significant risk of recurrent ulcer bleeding as PPI may increase the risk of small bowel bleeding. Our preliminary data provide strong plausibility that a combination therapy of misoprostol (MISO) with a PPI reduces the recurrent ulcer bleeding as well as clinical gastrointestinal bleeding. The investigators are going to provide the definitive answer to this important clinical question through a randomised trial.

Description

HYPOTHESIS The hypothesis that a combination therapy of misoprostol and lansoprazole is superior to lansoprazole alone for the prevention of recurrent ulcer bleeding in patients with a history of idiopathic ulcer bleeding.

STUDY DESIGN OVERVIEW It is a two-year, double blinded, randomized trial of a combination therapy with misoprostol with PPI (lansoprazole) versus misoprostol placebo plus PPI (lansoprazole) in patients with a history of idiopathic ulcer bleeding.

Randomization All eligible patients will be randomly assigned (in a 1:1 ratio) to receive 24 months of either misoprostol 800 micrograms daily (i.e. misoprostol 200 micrograms four times daily) combined with lansoprazole 30 mg once daily, or misoprostol placebo four times daily plus lansoprazole 30 mg once daily. A computer-generated randomisation schedule is used to assign patients to the treatment sequences. Concealment of allocation will be ascertained by an independent research staff member. The Clinical Research Pharmacy located in Prince of Wales Hospital will dispense consecutively numbered, identical packs that contain sealed bottles of the study medications.

Follow-up assessment After the randomisation visit, patients will return at month 2, month 6, and then every four months thereafter until 24 months (follow up 14 days from scheduled clinic visit is allowed). At each visit, patients' complete blood picture, renal and liver function tests, and serum salicylate level, compliance to study medications, and the use of other medications including over-the-counter drugs, and safety of the treatment will be assessed. Drug adherence is assessed by counting the study drugs. Patients are permitted to take antacids to relieve dyspepsia. Drugs prohibited during the study include anticoagulant agents, NSAIDs, cyclooxygenase-2 inhibitors, over-the-counter analgesics (including herbal products), corticosteroids, misoprostol, sucralfate, antiplatelet drugs, bisphosphonates, and PPIs/H2RAs apart from the study drugs.

:

Details
Condition Active Peptic Ulcer Disease/GI Bleeding, Active Peptic Ulcer Disease/GI Bleeding, Active Peptic Ulcer Disease/GI Bleeding, Active Peptic Ulcer Disease/GI Bleeding
Treatment Placebo Oral Tablet, Misoprostol Oral Tablet
Clinical Study IdentifierNCT03675672
SponsorChinese University of Hong Kong
Last Modified on4 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Idiopathic gastroduodenal ulcer bleeding is defined as described in our previous studies [12-15]
Gastroduodenal ulcer bleeding is diagnosed based on
i. History of symptoms of upper gastrointestinal bleeding with endoscopically
proven gastroduodenal ulcers
Idiopathic ulcer is diagnosed based on
i. No experience of ulcerogenic agents (e.g. aspirin, NSAIDs), or drugs of an
unknown nature including traditional Chinese medicine during the 4 weeks
before hospitalization of gastrointestinal bleeding episode; ii. Negative
biopsy urease test and absence of H. pylori on histology in the absence of
acid suppressive agents; and iii. No other cause of ulceration identified
(e.g. hypergastrinaemia, Crohn's disease, cytomegalovirus and herpes
infection)
\. Resume hemoglobin level which is same as or higher than the level prior to
last ulcer bleeding episode or stable hemoglobin level (drop <2g/dL) within
one year prior randomization iii.3. No reported gastroduodenal ulcer or ulcer
bleeding from last upper endoscopy 2.4. Aged 18 years old or above. 3.5
Written informed consent obtained. Fingerprint of subject with a witness
involved in the consent procedure will be accepted for illiterate subjects

Exclusion Criteria

Patients will be excluded from the study if they have any of the followings
Concomitant steroid or anticoagulant
Concomitant use of NSAIDs, aspirin or COX2 inhibitors
Previous gastric surgery
Requirement of maintenance PPI (e.g. reflux esophagitis)
Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above) or active malignancy
Subjects who are or will be pregnant or lactating
Subjects who have known hypersensitivity or allergies to any component of misoprostol and lansoprazole
Subject who has current or historical evidence of hypergastrinaemia syndrome or other hypersecretory condition
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note